Kearny Venture Partners
Kearny Venture Partners is a venture capital firm that focuses its investments on healthcare companies that produces novel therapies.
Business Model:
Revenue: $16M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Kearny Venture Partners Information
Geographic Data
Address: 88 Kearny St
City: San Francisco
State: CA
Zip: 94108
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
7,789,316Website Global Rank
459Website Monthly Traffic
Twitter Followers
Description
With over $330 million in capital under management, Kearny Venture Partners is a venture capital firm exclusively focused on healthcare products. We believe that the opportunity for entrepreneurs to devise innovative solutions in healthcare has never been greater. Significant unmet needs in healthcare continue to persist, representing large potential market opportunities for safe and effective products. As the molecular basis of disease is increasingly unraveled, new opportunities for intervention emerge. Novel therapies can and will displace incumbent products.
Contact Phone:
+14153645999
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2017 | ViewRay | Post-IPO Equity | 0 |
| 4/2014 | Aerpio Pharmaceuticals | Series C | 0 |
| 9/2008 | Baxano | Series B | 20M |
| 3/2017 | Aerpio Pharmaceuticals | Venture Round | 0 |
| 7/2015 | ViewRay | Post-IPO Equity | 0 |
| 8/2010 | TriVascular | Series C | 60M |
| 5/2013 | ViewRay | Venture Round | 15M |
| 3/2008 | TriVascular | Series A | 65M |
| 6/2010 | Baxano | Series C | 30M |
| 1/2011 | NextWave Pharmaceuticals | Series C | 45M |
| 6/2012 | TriVascular | Series D | 60M |
| 11/2009 | TriVascular | Series B | 30M |
| 11/2013 | TriVascular | Series E | 0 |
| 11/2013 | Aerpio Pharmaceuticals | Series A | 0 |
| 1/2008 | ViewRay | Series B | 25M |
| 12/2013 | ViewRay | Venture Round | 0 |
| 3/2012 | ViewRay | Series C | 45M |
| 8/2010 | ViewRay | Series C | 20M |
| 6/2013 | Akebia Therapeutics | Series C | 0 |
| 9/2011 | ViewRay | Debt Financing | 10M |
| 10/2013 | Boreal Genomics | Series C | 0 |
| 4/2011 | Akebia Therapeutics | Series B | 0 |
| 5/2007 | CVRx | Series D | 65M |
| 7/2009 | Akebia Therapeutics | Series A | 25M |
| 8/2016 | ViewRay | Post-IPO Equity | 0 |
| 7/2020 | Cybin | Series B | 0 |
| 7/2020 | Cybin | Series B | 0 |
| 3/2017 | Aerpio Pharmaceuticals | Venture Round | 0 |
| 1/2017 | ViewRay | Post-IPO Equity | 0 |
| 8/2016 | ViewRay | Post-IPO Equity | 0 |
| 7/2015 | ViewRay | Post-IPO Equity | 0 |
| 4/2014 | Aerpio Pharmaceuticals | Series C | 0 |
| 12/2013 | ViewRay | Venture Round | 0 |
| 11/2013 | TriVascular | Series E | 0 |
| 11/2013 | Aerpio Pharmaceuticals | Series A | 0 |
| 10/2013 | Boreal Genomics | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
